Literature DB >> 22460118

Aflibercept.

Michael W Stewart, Seden Grippon, Peter Kirkpatrick.   

Abstract

In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22460118     DOI： 10.1038/nrd3700

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  4 in total

1.  Ranibizumab.

Authors:  Raja Narayanan; Baruch D Kuppermann; Carole Jones; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2006-10       Impact factor: 84.694

Review 2.  The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.

Authors:  Michael W Stewart
Journal:  Mayo Clin Proc       Date:  2012-01       Impact factor: 7.616

3.  Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Authors:  Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

4.  VEGF-Trap: a VEGF blocker with potent antitumor effects.

Authors:  Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205
  4 in total
  27 in total

1.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 2.  Anti-vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future.

Authors:  Tsong Qiang Kwong; Moin Mohamed
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

3.  Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment.

Authors:  E Al Kahtani; Z Xu; S Al Rashaed; L Wu; A Mahale; J Tian; E B Abboud; N G Ghazi; I Kozak; V Gupta; J F Arevalo; E J Duh
Journal:  Eye (Lond)       Date:  2016-11-25       Impact factor: 3.775

Review 4.  Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Kristina Lindsley; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2014-05-01

5.  Receptor mediated disruption of retinal pigment epithelium function in acute glycated-albumin exposure.

Authors:  Mohammad Dahrouj; Danielle M Desjardins; Yueying Liu; Craig E Crosson; Zsolt Ablonczy
Journal:  Exp Eye Res       Date:  2015-06-10       Impact factor: 3.467

6.  Sema3C promotes the survival and tumorigenicity of glioma stem cells through Rac1 activation.

Authors:  Jianghong Man; Jocelyn Shoemake; Wenchao Zhou; Xiaoguang Fang; Qiulian Wu; Anthony Rizzo; Richard Prayson; Shideng Bao; Jeremy N Rich; Jennifer S Yu
Journal:  Cell Rep       Date:  2014-11-20       Impact factor: 9.423

Review 7.  Aflibercept for intravitreal injection: in neovascular age-related macular degeneration.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

Review 8.  Clinical pharmacology of intravitreal anti-VEGF drugs.

Authors:  Stefano Fogli; Marzia Del Re; Eleonora Rofi; Chiara Posarelli; Michele Figus; Romano Danesi
Journal:  Eye (Lond)       Date:  2018-02-05       Impact factor: 3.775

9.  Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting.

Authors:  Peter D Westenskow; Toshihide Kurihara; Edith Aguilar; Elizabeth L Scheppke; Stacey K Moreno; Carli Wittgrove; Valentina Marchetti; Iacovos P Michael; Sudarshan Anand; Andras Nagy; David Cheresh; Martin Friedlander
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

10.  Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.

Authors:  Sarath K Yandrapu; Arun K Upadhyay; J Mark Petrash; Uday B Kompella
Journal:  Mol Pharm       Date:  2013-11-12       Impact factor: 4.939
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.